Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, pp.1415-1441, 2016. ,
DOI : 10.1016/S0140-6736(16)00004-0
Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-567, 2007. ,
DOI : 10.1016/S0002-9440(10)62574-6
-Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-94, 2013. ,
DOI : 10.1056/NEJMoa1214886
URL : https://hal.archives-ouvertes.fr/hal-00953826
-Positive Lung Cancer, New England Journal of Medicine, vol.371, issue.23, pp.2167-77, 2014. ,
DOI : 10.1056/NEJMoa1408440
URL : https://hal.archives-ouvertes.fr/halshs-00919639
First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). in, 2016. ,
Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study, Annals of Oncology, vol.27, issue.suppl_6, 2016. ,
DOI : 10.1093/annonc/mdw435.41
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, The Lancet Oncology, vol.15, issue.10, pp.1119-1147, 2014. ,
DOI : 10.1016/S1470-2045(14)70362-6
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models, Cancer Cell, vol.28, issue.1, pp.70-81, 2015. ,
DOI : 10.1016/j.ccell.2015.05.010
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial, The Lancet Oncology, vol.17, issue.12, pp.1683-1696, 2016. ,
DOI : 10.1016/S1470-2045(16)30392-8
Rearranged Non???Small-Cell Lung Cancer: A Phase II Global Study, Journal of Clinical Oncology, vol.34, issue.7, pp.661-669, 2016. ,
DOI : 10.1200/JCO.2015.63.9443
Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, The Lancet Oncology, vol.17, issue.2, pp.234-276, 2016. ,
DOI : 10.1016/S1470-2045(15)00488-X
New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer, Current Treatment Options in Oncology, vol.7, issue.12, p.49, 2015. ,
DOI : 10.1097/JTO.0b013e3182745948
FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.21, issue.11, pp.2436-2439, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-3157
Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer, Expert Review of Respiratory Medicine, vol.23, issue.152, pp.255-268, 2015. ,
DOI : 10.1158/1078-0432.CCR-12-3381
Overall survival with crizotinib and next-generation ALK inhibitors in ALKpositive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study, Oncotarget ,
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, vol.8, pp.823-859, 2013. ,
Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non???Small-Cell Lung Cancers Reveal Major Discordances, Journal of Thoracic Oncology, vol.9, issue.3, pp.295-306, 2014. ,
DOI : 10.1097/JTO.0000000000000072
URL : https://hal.archives-ouvertes.fr/hal-01064002
???borderline???-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies, Annals of Oncology, vol.26, issue.1, pp.238-282, 2015. ,
DOI : 10.1093/annonc/mdu484
rearrangement diagnostic in 547 lung adenocarcinomas, European Respiratory Journal, vol.46, issue.1, pp.207-218, 2015. ,
DOI : 10.1183/09031936.00119914
ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making, Lung Cancer, vol.90, issue.3, pp.465-71, 2015. ,
DOI : 10.1016/j.lungcan.2015.09.022
ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues, Oncology Reports, vol.36, issue.3, pp.1427-1461, 2016. ,
DOI : 10.3892/or.2016.4962
ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm, Journal of Thoracic Oncology, vol.11, issue.4, pp.487-95, 2016. ,
DOI : 10.1016/j.jtho.2015.12.111
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants, Journal of Translational Medicine, vol.24, issue.1, p.296, 2016. ,
DOI : 10.1093/annonc/mds242
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC, Clinical Lung Cancer, vol.17, issue.3, pp.223-254, 2016. ,
DOI : 10.1016/j.cllc.2015.09.002
-rearranged non???small cell lung cancer, Annals of Oncology, vol.693, 2016. ,
DOI : 10.1093/annonc/mdw693
URL : https://hal.archives-ouvertes.fr/tel-01488898
-Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3392, 2016. ,
DOI : 10.1200/JCO.2015.65.8732
URL : https://hal.archives-ouvertes.fr/hal-01486034
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants, Clinical Cancer Research, vol.18, issue.17, pp.4682-90, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-3260
Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives, Briefings in Bioinformatics, vol.14, issue.4, pp.506-519, 2013. ,
DOI : 10.1093/bib/bbs044
Anchored multiplex PCR for targeted next-generation sequencing, Nature Medicine, vol.40, issue.12, pp.1479-84, 2014. ,
DOI : 10.1093/nar/gks596
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches, Clinical Cancer Research, vol.21, issue.16, pp.3631-3640, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2683
Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer, The Oncologist, vol.20, issue.3, pp.316-322, 2015. ,
DOI : 10.1634/theoncologist.2014-0389
ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology, Annals of Oncology, vol.27, issue.suppl_3, pp.25-34, 2016. ,
DOI : 10.1093/annonc/mdw303
Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH??and IHC in Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.11, issue.11, pp.1891-1900, 2016. ,
DOI : 10.1016/j.jtho.2016.06.001
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients, Journal of Thoracic Oncology, vol.10, issue.7, pp.1049-1057, 2015. ,
DOI : 10.1097/JTO.0000000000000570
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-85, 2011. ,
DOI : 10.1097/JTO.0b013e318206a221
URL : https://hal.archives-ouvertes.fr/inserm-00561753
The 2015 World Health Organization Classification of Lung Tumors, Journal of Thoracic Oncology, vol.10, issue.9, pp.1243-1260, 2015. ,
DOI : 10.1097/JTO.0000000000000630
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC, Journal of Experimental & Clinical Cancer Research, vol.30, issue.1, 2011. ,
DOI : 10.1158/1078-0432.CCR-05-2324
URL : https://hal.archives-ouvertes.fr/inserm-00602408
Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study, Journal of Thoracic Oncology, vol.7, issue.2, pp.348-54, 2012. ,
DOI : 10.1097/JTO.0b013e3182381535
High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer, Genes, Chromosomes and Cancer, vol.20, issue.1, pp.30-44, 2016. ,
DOI : 10.1038/nm.3729
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease, The Lancet, vol.388, issue.10048, pp.1002-1013, 2016. ,
DOI : 10.1016/S0140-6736(16)31340-X
Coming of age: ten years of next-generation sequencing technologies, Nature Reviews Genetics, vol.4, issue.6, pp.333-351, 2016. ,
DOI : 10.1111/j.1755-0998.2011.03024.x
-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization, The Oncologist, vol.21, issue.6, pp.762-70, 2016. ,
DOI : 10.1634/theoncologist.2015-0497
URL : https://hal.archives-ouvertes.fr/hal-01483447
Novel ALK fusion partners in lung cancer, Cancer Letters, vol.362, issue.1, pp.116-121, 2015. ,
DOI : 10.1016/j.canlet.2015.03.028
The role of the ALK receptor in cancer biology, Annals of Oncology, vol.27, issue.suppl_3, pp.4-15, 2016. ,
DOI : 10.1093/annonc/mdw301
An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer: Figure 1., Annals of Oncology, vol.26, issue.8, pp.1800-1801, 2015. ,
DOI : 10.1093/annonc/mdv240
Comprehensive Hybrid Capture???Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH, Journal of Thoracic Oncology, vol.12, issue.3, pp.22-24, 2017. ,
DOI : 10.1016/j.jtho.2016.11.2229
-Rearranged Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.371, issue.21, pp.1963-1971, 2014. ,
DOI : 10.1056/NEJMoa1406766
URL : https://hal.archives-ouvertes.fr/hal-00953826
Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma, Lung Cancer, vol.101, pp.16-21, 2016. ,
DOI : 10.1016/j.lungcan.2016.09.002
Differential protein stability and clinical responses of EML4-ALKfusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, 2016. ,
-Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, pp.10-1056, 2017. ,
DOI : 10.1056/NEJMoa1704795
URL : https://hal.archives-ouvertes.fr/hal-01485931
-Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-2394, 2013. ,
DOI : 10.1056/NEJMoa1214886
URL : https://hal.archives-ouvertes.fr/hal-00953826
-Positive Lung Cancer, PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer, pp.2167-2177, 2014. ,
DOI : 10.1056/NEJMoa1408440
URL : https://hal.archives-ouvertes.fr/halshs-00919639
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ,
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, The Lancet Oncology, vol.17, issue.4, pp.452-463, 2016. ,
DOI : 10.1016/S1470-2045(15)00614-2
Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.18, issue.7, 2017. ,
DOI : 10.1016/S1470-2045(17)30339-X
Differential protein stability and clinical responses of EML4-ALKfusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer, Ann. Oncol, 2016. ,
-Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3389, 2016. ,
DOI : 10.1200/JCO.2015.65.8732
URL : https://hal.archives-ouvertes.fr/hal-01486034
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib, Clinical Cancer Research, vol.21, issue.12, pp.2745-2752, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-3009
KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only, PLoS ONE, vol.12, issue.2, p.31323, 2012. ,
DOI : 10.1371/journal.pone.0031323.s002
-Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, 2017. ,
DOI : 10.1056/NEJMoa1704795
URL : https://hal.archives-ouvertes.fr/hal-01485931
Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions, The American Journal of Surgical Pathology, vol.39, issue.5, pp.581-591, 2015. ,
DOI : 10.1097/PAS.0000000000000387
Targeting ALK: Precision Medicine Takes on Drug Resistance, Cancer Discovery, vol.7, issue.2, pp.137-155, 2017. ,
DOI : 10.1158/2159-8290.CD-16-1123
CLIP-170 links endocytic vesicles to microtubules, Cell, vol.70, issue.6, pp.887-900, 1992. ,
DOI : 10.1016/0092-8674(92)90240-D
Regulation of tumor angiogenesis by the microtubule-binding protein CLIP-170, Protein & Cell, vol.17, issue.4, pp.266-276, 2013. ,
DOI : 10.1038/nm.2537
The 2015 World Health Organization Classification of Lung Tumors, Journal of Thoracic Oncology, vol.10, issue.9, pp.1243-1260, 2015. ,
DOI : 10.1097/JTO.0000000000000630
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma, Modern Pathology, vol.6, issue.4, pp.511-522, 2013. ,
DOI : 10.1200/JCO.2007.15.0375
Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology, Virchows Archiv, vol.29, issue.1, pp.61-68, 2014. ,
DOI : 10.1007/s10555-010-9205-8
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.15 ,
DOI : 10.1158/1078-0432.CCR-13-0318
Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer, Oncotarget, vol.6, issue.26, pp.22028-22037, 2015. ,
DOI : 10.18632/oncotarget.4314
Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma, Clinical Lung Cancer, vol.18, issue.3, pp.197-201, 2017. ,
DOI : 10.1016/j.cllc.2016.11.014
A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4???ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib, Journal of Thoracic Oncology, vol.9, issue.6 ,
DOI : 10.1097/JTO.0000000000000103
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies, Journal of Thoracic Oncology, vol.8, issue.8, pp.75-78, 2013. ,
DOI : 10.1097/JTO.0b013e318293d96f
Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma, Lung Cancer, vol.92, pp.15-18, 2016. ,
DOI : 10.1016/j.lungcan.2015.12.001
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors, Science Translational Medicine, vol.105, issue.34, pp.75-101, 2011. ,
DOI : 10.1073/pnas.0803217105
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants, Clinical Cancer Research, vol.18, issue.17, pp.4682-4690, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-3260
-Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3389, 2016. ,
DOI : 10.1200/JCO.2015.65.8732
URL : https://hal.archives-ouvertes.fr/hal-01486034
-rearranged non???small cell lung cancer, Annals of Oncology, vol.693, 2016. ,
DOI : 10.1093/annonc/mdw693
URL : https://hal.archives-ouvertes.fr/tel-01488898
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, 2016. ,
DOI : 10.1016/S0140-6736(16)00004-0
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. eLife [Internet] Available from, 2015. ,
Augmentor ?? and ?? (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand???receptor interactions, Proceedings of the National Academy of Sciences, vol.9, issue.6, pp.15862-15869, 2015. ,
DOI : 10.7554/eLife.09811
Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-567, 2007. ,
DOI : 10.1016/S0002-9440(10)62574-6
Anaplastic Lymphoma Kinase Inhibition in Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.363, issue.18, pp.1693-703, 2010. ,
DOI : 10.1056/NEJMoa1006448
ALK signaling and target therapy in anaplastic large cell lymphoma Available from, Front Oncol, vol.2, 2012. ,
New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers. Clin Cancer Res, pp.7213-7221, 2011. ,
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population, Clinical Cancer Research, vol.15, issue.16, pp.5216-5239, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-0802
-Positive Lung Cancer, New England Journal of Medicine, vol.371, issue.23, pp.2167-77, 2014. ,
DOI : 10.1056/NEJMoa1408440
URL : https://hal.archives-ouvertes.fr/halshs-00919639
-Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-94, 2013. ,
DOI : 10.1056/NEJMoa1214886
URL : https://hal.archives-ouvertes.fr/hal-00953826
Molecular Mechanisms of Resistance to First-and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov, pp.1118-1151, 2016. ,
Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.18, issue.7, 2017. ,
DOI : 10.1016/S1470-2045(17)30339-X
-Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, 2017. ,
DOI : 10.1056/NEJMoa1704795
URL : https://hal.archives-ouvertes.fr/hal-01485931
Crizotinib resistance: implications for therapeutic strategies, Annals of Oncology, vol.27, issue.suppl_3, pp.42-50, 2016. ,
DOI : 10.1093/annonc/mdw305
-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology, The Oncologist, vol.17, issue.11, pp.1351-75, 2012. ,
DOI : 10.1634/theoncologist.2012-0311
URL : https://hal.archives-ouvertes.fr/halshs-01556558
: Honing In on a New Target in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.26, pp.4232-4237, 2009. ,
DOI : 10.1200/JCO.2009.23.6661
The biology and treatment of EML4-ALK non-small cell lung cancer, European Journal of Cancer, vol.46, issue.10, pp.1773-80, 1990. ,
DOI : 10.1016/j.ejca.2010.04.002
Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov, Feb, vol.7, issue.2, pp.137-55, 2017. ,
DOI : 10.1158/2159-8290.cd-16-1123
French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas, Eur Respir J, p.2015 ,
Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non???Small-Cell Lung Cancers Reveal Major Discordances, Journal of Thoracic Oncology, vol.9, issue.3, pp.295-306 ,
DOI : 10.1097/JTO.0000000000000072
URL : https://hal.archives-ouvertes.fr/hal-01064002
ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm, Journal of Thoracic Oncology, vol.11, issue.4, 2016. ,
DOI : 10.1016/j.jtho.2015.12.111
Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by, PLoS ONE Jul, vol.39, issue.7, p.101551, 2014. ,
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays, Lung Cancer, vol.99, pp.11-17, 2016. ,
DOI : 10.1016/j.lungcan.2016.06.005
Initial sequencing and analysis of the human genome, Nature, vol.6, issue.6822, pp.860-921, 2001. ,
DOI : 10.1089/cmb.1999.6.91
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service, PLOS Medicine, vol.3, issue.6, p.1002230, 2017. ,
DOI : 10.1371/journal.pmed.1002230.s018
Mutational landscape and significance across 12 major cancer types, Nature, vol.339, issue.7471, pp.333-342, 2013. ,
DOI : 10.1126/science.1235122
URL : http://www.nature.com/nature/journal/v502/n7471/pdf/nature12634.pdf
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients, Journal of Thoracic Oncology, vol.10, issue.7, pp.1049-57 ,
DOI : 10.1097/JTO.0000000000000570
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non???Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments, Clinical Lung Cancer, 2017. ,
DOI : 10.1016/j.cllc.2017.06.008
Transcriptome sequencing to detect gene fusions in cancer, Nature, vol.3, issue.7234, pp.97-101, 2009. ,
DOI : 10.1101/gr.229202. Article published online before March 2002
Anchored multiplex PCR for targeted next-generation sequencing, Nature Medicine, vol.40, issue.12, pp.1479-84, 2014. ,
DOI : 10.1093/nar/gks596
Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing, Lung Cancer, vol.84, issue.3, 2014. ,
DOI : 10.1016/j.lungcan.2014.03.002
High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer, Genes, Chromosomes and Cancer, vol.20, issue.1, pp.30-44, 2016. ,
DOI : 10.1038/nm.3729
Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep, Feb, vol.97, p.42259, 2017. ,
Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer, Annals of Oncology, vol.475, 2015. ,
DOI : 10.1093/annonc/mdv475
Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. The Oncologist, pp.316-338, 2015. ,
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nature Biotechnology, vol.11, issue.11, pp.1023-1054, 2013. ,
DOI : 10.1093/NAR/29.1.308
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches, Clinical Cancer Research, vol.21, issue.16, pp.3631-3640, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2683
ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology, Annals of Oncology, vol.27, issue.suppl_3, pp.25-34, 2016. ,
DOI : 10.1093/annonc/mdw303
-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization, The Oncologist, vol.21, issue.6, 2016. ,
DOI : 10.1634/theoncologist.2015-0497
URL : https://hal.archives-ouvertes.fr/hal-01483447
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res, pp.2745-52, 2015. ,
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis, Lung Cancer, vol.90, issue.2, pp.255-60, 2015. ,
DOI : 10.1016/j.lungcan.2015.09.009
Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions, The American Journal of Surgical Pathology, vol.39, issue.5, pp.581-91 ,
DOI : 10.1097/PAS.0000000000000387
-Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3392, 2016. ,
DOI : 10.1200/JCO.2015.65.8732
URL : https://hal.archives-ouvertes.fr/hal-01486034
-rearranged non???small cell lung cancer, Annals of Oncology, vol.693, 2016. ,
DOI : 10.1093/annonc/mdw693
URL : https://hal.archives-ouvertes.fr/tel-01488898
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC, Clinical Lung Cancer, vol.17, issue.3, pp.223-254, 2016. ,
DOI : 10.1016/j.cllc.2015.09.002
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants Available from, J Transl Med, vol.14, issue.1, 2009. ,
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants, Clinical Cancer Research, vol.18, issue.17, pp.4682-90, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-3260
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical ??-propeller domain, Proceedings of the National Academy of Sciences, vol.66, issue.Pt 1, pp.5195-200, 2014. ,
DOI : 10.1107/S0907444909042073
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK???positive lung cancer, Nature Medicine, vol.511, issue.9, pp.1038-1085, 2015. ,
DOI : 10.1158/1078-0432.CCR-10-0851
Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens, The Journal of Molecular Diagnostics, vol.15, issue.2, pp.234-281, 2013. ,
DOI : 10.1016/j.jmoldx.2012.11.006
Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms, Cancer Cytopathology, vol.31, issue.suppl 1, pp.688-94, 2013. ,
DOI : 10.1007/s10637-012-9891-x
Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung, Cancer Cytopathology, vol.12, issue.2, pp.104-117, 2014. ,
DOI : 10.2353/jmoldx.2010.090238
Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology. Sci Rep [Internet] Available from, 2015. ,
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA, PLOS ONE, vol.17, issue.Suppl 5, p.140712, 2015. ,
DOI : 10.1371/journal.pone.0140712.s006
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay, Oncotarget, vol.7, issue.9, pp.9707-9724, 2016. ,
DOI : 10.18632/oncotarget.7110